Shares Of Ligand Follow Parabolic Curve Amid Responses Surrounding Promacta's Phase III Trial
June 17, 2014 at 12:26 PM EDT
Shares of Ligand Pharmaceuticals (NASDAQ: LGND) are down again following the results of the Phase III trial of Promacta. GSK Releases ...